Publications

  1. Toth RK, Solomon R, Warfel NA. Stabilization of PIM kinases in hypoxia is mediated by the deubiquitinase USP28. Cells (2022) PMID: 35326457.
  2. Ryniawec JM, Coope MR, Loertscher E, Bageerathan V, de Oliveira Pessoa D, Warfel NA, Cress AE, Padi M, Rogers GC. GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics 2022 PMID: 35328229.
  3. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. (2021) PMID: 34934057.
  4. Casillas AL, Chauhan SS, Toth RK, Sainz AG, Clements AN, Jensen CC, Langlais PR, Miranti CK, Cress AE, Warfel NA. Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors. Oncogene. (2021) PMID: 34211090.
  5. Chauhan SS, Toth RK, Jensen CC, Casillas AL, Kashatus DF, Warfel NA. PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer. Oncogene (2020) PMID: 31992853.
  6. Rubenstein CS, Gard JMC, Wang M, McGrath JE, Ingabire N, Hinton JP, Marr KD, Simpson SJ, Nagle RB, Miranti CK, Warfel NA, Garcia JGN, Arif-Tiwari H, Cress AE. Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer. Cancer Res 79(18):4703-4714 (2019) PMID: 31337652
  7. Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol 7(4):297-312 (2019) PMID: 31511835
  8. Song JH, Singh N, Luevano L, Padi S, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, and Kraft AS. Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase. Molecular Cancer Therapeutics (2018). PMID: 30190422
  9. Casillas AL, Toth RK, Singh N, Desai AA, Kraft AS, and Warfel NA. Hypoxia-inducible PIM kinase expression promotes resistance to antiangiogenic agents. Clinical Cancer Research (2018). PMID: 29084916
  10. Warfel NA*, Sainz AG, Song JH, Kraft AS*. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Molecular Cancer Therapeutics. (2016). *co-corresponding authors. PMID: 27196781
  11. Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft A.S. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. (2016). PMID: 26956053
  12. Zhang S, Zhou L, Hong B., van den Heuvel AP., Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer research, (2015). PMID: 26294215
  13. Warfel NA, Dolloff N, Dicker DT., Malysz J, El-Diery WS, CDK1-mediated phosphorylation of Ser668 stabilizes HIF-1a to promote tumor growth. Cell Cycle (2013). PMID: 24189531
  14. Warfel NA, Niederst M, Stevens MW, Brennan PM, Frame MC, Newton AC. Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem 286, 19777 (2011). PMID: 21454620
  15. Warfel NA, Niederst M, Newton AC. Disruption of the interface between the PH and kinase domains of Akt is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem,  (2011). PMID: 21908613
  16. Brognard J, Niederst M, Reyes G, Warfel NA, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J Biol Chem 284, 15215 (2009). PMID: 19324870
  17. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13, 5183 (2007). PMID: 17785575
  18. Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel NA, Han J, Kozikowski AP, Dennis PA. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem 282, 27020 (2007). PMID: 17631503
  19. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq TJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13, 2281 (2007). PMID: 17404113
  20. Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res 12, 3502 (2006). PMID: 16740776

Invited review articles and commentaries

  1. Warfel NA. Defining the mechanisms underlying cyclin dependent kinase control of HIF-1a. Oncotarget. (2022). PMID: 35251493.
  2. Toth RK, Warfel NA. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer. Mol Cancer Ther. (2021) 2020 Dec 10. Review. PubMed PMID: 33303645.
  3. Harryman WL, Warfel NA, Nagle RB, Cress AE. The Tumor Microenvironments of Lethal Prostate Cancer. Adv Exp Med Biol 1210:149-170 (2019) PMID: 31900909
  4. Chauhan SS and Warfel NA. Targeting PIM kinase to Oppose Hypoxia-mediated Therapeutic Resistance. Oncoscience (2018). PMID: 30460324
  5. Warfel NA. Targeting CDK4/6 to Oppose Hypoxia-Mediated Therapeutic Resistance. Cell Cycle. (2017). PMID: 28594259
  6. Toth RK and Warfel NA. Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-inducible Factor 1 (HIF-1) in Tumor Hypoxia. Antioxidants, (2017). PMID: 28383481
  7. Warfel NA and Kraft AS. PIM Kinase (and Akt) Biology and Signaling in Tumors. Pharmacology and Therapeutics, (2015). PMID: 25749412 
  8. Warfel NA and El-Deiry WS. HIF-1 Signaling in Drug Resistance to Chemotherapy. Curr Med Chem, (2014). PMID: 24735366
  9. Warfel NA and El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25, 52 (Jan, 2013). PMID: 23159848 
  10. Prabhu VV, Warfel NA, El-Deiry WS. CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle, (2012). PMID: 22751431 
  11. Warfel NA and Newton AC. PH domain Leucine-rich Repeat Protein Phosphatase, PHLPP: a New Player in Cell Signaling. J Biol Chem,  (2011). PMID: 22144674